Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02306850
Title Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Acronym NeoPembroMel
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors St. Louis University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Saint Louis University Hospital Saint Louis Missouri 63101 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field